China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China · Delayed Price · Currency is CNY 27.23
-0.18 (-0.66%)
Aug 22, 2025, 3:04 PM CST
SHE:300294 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 306.36 | 396.99 | 237.47 | 432.2 | 344.53 | 260.06 | Upgrade |
Depreciation & Amortization | 134.76 | 100.87 | 98.57 | 97.03 | 99.35 | 81.34 | Upgrade |
Other Amortization | 14.63 | 16.09 | 15.39 | 13.74 | 13.63 | 13.26 | Upgrade |
Loss (Gain) From Sale of Assets | -4.79 | 0.61 | -1.3 | -0.07 | 0.87 | 1.58 | Upgrade |
Asset Writedown & Restructuring Costs | 56.66 | 83.8 | 326.72 | 53.65 | 80.57 | 0.27 | Upgrade |
Loss (Gain) From Sale of Investments | -35.38 | -78.64 | -99.75 | -43.84 | -43.11 | -10.14 | Upgrade |
Provision & Write-off of Bad Debts | 2.91 | 8.79 | 2.37 | 2.8 | 0.05 | -9.29 | Upgrade |
Other Operating Activities | -2.99 | -3.53 | 14.46 | 13.92 | 31.26 | 38.39 | Upgrade |
Change in Accounts Receivable | -402.49 | -211.49 | 40.02 | -11.73 | 799.83 | 390.43 | Upgrade |
Change in Inventory | -125.25 | -120.06 | 107.01 | 1.28 | 11.77 | -68.54 | Upgrade |
Change in Accounts Payable | 151.27 | 116.59 | -92.32 | 56.24 | 4.14 | 15.9 | Upgrade |
Change in Unearned Revenue | -4.01 | -4.01 | -3.57 | -4.13 | -1.46 | - | Upgrade |
Change in Other Net Operating Assets | - | - | - | 3.28 | 11.59 | - | Upgrade |
Operating Cash Flow | 95.07 | 299.78 | 641.73 | 596.44 | 1,345 | 718.58 | Upgrade |
Operating Cash Flow Growth | -79.34% | -53.29% | 7.59% | -55.67% | 87.23% | - | Upgrade |
Capital Expenditures | -427.39 | -197.79 | -87.5 | -138.41 | -68.12 | -142.51 | Upgrade |
Sale of Property, Plant & Equipment | 2.36 | 1.82 | 3.26 | 0.33 | 4.41 | 1.66 | Upgrade |
Cash Acquisitions | -1,778 | -1,778 | - | - | - | - | Upgrade |
Divestitures | 130.18 | 239.61 | 269 | - | - | - | Upgrade |
Investment in Securities | -111.6 | 975.51 | -248.85 | -500 | -2,505 | 7.02 | Upgrade |
Other Investing Activities | 84.91 | 111.26 | 78.33 | 77.86 | 32.4 | 5.5 | Upgrade |
Investing Cash Flow | -2,099 | -647.53 | 14.25 | -560.22 | -2,536 | -128.34 | Upgrade |
Long-Term Debt Issued | - | - | 22.15 | - | 251.85 | 820 | Upgrade |
Long-Term Debt Repaid | - | -76.3 | -24.98 | -3.82 | -563.55 | -1,113 | Upgrade |
Net Debt Issued (Repaid) | -74.36 | -76.3 | -2.83 | -3.82 | -311.7 | -292.56 | Upgrade |
Issuance of Common Stock | - | - | - | - | 2,400 | - | Upgrade |
Common Dividends Paid | -161.81 | -232.41 | -100.85 | -83.19 | -46.03 | -88.81 | Upgrade |
Other Financing Activities | -3.48 | 5.24 | -132.97 | 2 | -9.64 | -9.09 | Upgrade |
Financing Cash Flow | -239.66 | -303.47 | -236.65 | -85.01 | 2,032 | -390.46 | Upgrade |
Net Cash Flow | -2,244 | -651.23 | 419.33 | -48.79 | 841.39 | 199.78 | Upgrade |
Free Cash Flow | -332.32 | 101.99 | 554.23 | 458.03 | 1,277 | 576.07 | Upgrade |
Free Cash Flow Growth | - | -81.60% | 21.00% | -64.14% | 121.72% | - | Upgrade |
Free Cash Flow Margin | -17.99% | 5.88% | 20.90% | 16.60% | 48.19% | 22.92% | Upgrade |
Free Cash Flow Per Share | -0.66 | 0.20 | 1.10 | 0.91 | 2.93 | 1.35 | Upgrade |
Cash Income Tax Paid | 90.73 | 167.06 | 250.39 | 227.94 | 192.85 | 190.04 | Upgrade |
Levered Free Cash Flow | -325.26 | 16.4 | 376.4 | 354.85 | 1,141 | 449.92 | Upgrade |
Unlevered Free Cash Flow | -324.63 | 16.82 | 376.68 | 355.24 | 1,148 | 463.33 | Upgrade |
Change in Working Capital | -377.1 | -225.2 | 47.79 | 27.01 | 818.22 | 343.11 | Upgrade |
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.